John G Matthews
Overview
Explore the profile of John G Matthews including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1621
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeng X, Qing J, Li C, Lu J, Yamawaki T, Hsu Y, et al.
J Allergy Clin Immunol
. 2023 Jun;
152(4):876-886.
PMID: 37315813
Background: Patients with type-2 (T2) cytokine-low severe asthma often have persistent symptoms despite suppression of T2 inflammation with corticosteroids. Objectives: We sought to analyze whole blood transcriptome from 738 samples...
2.
Eastwood M, Busby J, Jackson D, Pavord I, Hanratty C, Djukanovic R, et al.
J Allergy Clin Immunol Pract
. 2023 Jan;
11(4):1233-1242.e5.
PMID: 36621603
Background: Approximately 5% to 10% of patients with asthma have severe disease, with a consistent preponderance in females. Current asthma guidelines recommend stepwise treatment to achieve symptom control with no...
3.
Szefler S, Roberts G, Rubin A, Zielen S, Kuna P, Alpan O, et al.
Clin Transl Allergy
. 2022 Jul;
12(7):e12176.
PMID: 35846226
Background: Lebrikizumab is a monoclonal antibody that modulates activity of interleukin-13. The Phase 3 ACOUSTICS study assessed lebrikizumab efficacy and safety in adolescents with uncontrolled asthma despite standard-of-care treatment. Methods:...
4.
McDowell P, Busby J, Hanratty C, Djukanovic R, Woodcock A, Walker S, et al.
Am J Respir Crit Care Med
. 2022 May;
206(5):545-553.
PMID: 35549845
The past 25 years have seen huge progress in understanding of the pathobiology of type-2 (T2) asthma, identification of measurable biomarkers, and the emergence of novel monoclonal antibody treatments. Although...
5.
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma
Busby J, Matthews J, Chaudhuri R, Pavord I, Hardman T, Arron J, et al.
Eur Respir J
. 2021 Sep;
59(4).
PMID: 34561291
Background: Understanding why patients with severe asthma do not follow healthcare provider (HCP) advice to adjust treatment is critical to achieving personalised disease management. Methods: We reviewed patient choice to...
6.
Busby J, Holweg C, Chai A, Bradding P, Chaudhuri R, Mansur A, et al.
Pulm Pharmacol Ther
. 2020 Oct;
64:101951.
PMID: 33045343
Background And Objective: Non-adherence is an important issue within severe asthma. Prednisolone and cortisol assays have been proposed as an inexpensive, objective measure of adherence for oral corticosteroid (OCS)-dependent asthmatics,...
7.
Heaney L, Busby J, Hanratty C, Djukanovic R, Woodcock A, Walker S, et al.
Lancet Respir Med
. 2020 Sep;
9(1):57-68.
PMID: 32916135
Background: Asthma treatment guidelines recommend increasing corticosteroid dose to control symptoms and reduce exacerbations. This approach is potentially flawed because symptomatic asthma can occur without corticosteroid responsive type-2 (T2)-driven eosinophilic...
8.
Austin C, Edick M, Ferrando R, Solon M, Baca M, Mesh K, et al.
Clin Exp Allergy
. 2020 Sep;
50(12):1342-1351.
PMID: 32909660
Background: The anti-interleukin 13 (IL-13) monoclonal antibody lebrikizumab improves lung function in patients with moderate-to-severe uncontrolled asthma, but its effects on airway inflammation and remodelling are unknown. CLAVIER was designed...
9.
Bauer R, Yang X, Staton T, Olsson J, Holweg C, Arron J, et al.
BMJ Open Respir Res
. 2019 Dec;
6(1):e000406.
PMID: 31803473
Introduction: Asthma exacerbations spike in the spring and autumn months, yet the seasonal variation of asthma symptoms and lung function is poorly studied. Methods: Seasonal variation of lung function, rescue...
10.
Busby J, Holweg C, Chai A, Bradding P, Cai F, Chaudhuri R, et al.
Thorax
. 2019 Apr;
74(8):806-809.
PMID: 30940770
Type-2 biomarkers and related cytokines (IL-5, IL-13), lung function and asthma symptoms were measured in 44 poorly-controlled severe oral corticosteroid (OCS)-dependent asthmatics for up to 88 days after a 7-day...